SAN MATEO, Calif., May 15 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX), a biopharmaceutical company focused on developing novel
pain management therapies, announced today that it is scheduled to present
on Monday, May 19, 2008 at the Rodman & Renshaw 5th Annual Global
Healthcare Conference. Anthony DiTonno, President and Chief Executive
Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer,
will be available to respond to questions.
Event: Rodman & Renshaw 5th Annual Global Healthcare Conference
Date: Monday, May 19, 2008
Time: 5:15 p.m. CEST
Place: Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco
An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the United States Food and Drug Administration (FDA) in 2008 for PHN.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, the timing of presentations by
NeurogesX and the expected benefits of NeurogesX' potential products,
including its lead product candidate NGX-4010. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to,
NeurogesX' product candidate may have unexpected adverse side effects or
inadequate therapeutic efficacy; positive results in clinical trials may
not be sufficient to obtain FDA or European regulatory approval; physician
or patient reluctance to use NGX-4010, if approved, or the inability of
physicians to obtain sufficient reimbursement for such procedures;
potential alternative therapies; maintaining adequate patent or trade
secret protection without violating the intellectual property rights of
others; and other difficulties or delays in clinical development, obtaining
regulatory approval, market acceptance and commercialization of NGX- 4010
and the advantages of NGX-4010 over other pain therapies. For further
information regarding these and other risks related to NeurogesX' business,
investors should consult NeurogesX' filings with the Securities and
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved